Answers are grounded in this paper and cite their sources.
Rapid hotspot mutation testing offers a practical route to integrated glioma diagnosis when tissue availability, turnaround time, or sequencing capacity is limited. We validated the MeltArray Glioma Assay, a laboratory-developed test that detects 18 hotspot mutations across IDH1, IDH2, TERT, histone H3 genes, and BRAF using only two reactions in a four-channel format. Analytical performance was assessed with respect to melting-temperature reproducibility, lowest tested detectable input, mutant allele fraction sensitivity, specificity, and the function of the RPP30 internal control. Assay calls in 168 formalin-fixed, paraffin-embedded gliomas were compared with targeted next-generation sequencing. Melting temperatures were highly reproducible across three independent SLAN-96S instruments of the same model (coefficients of variation, 0.07–0.48%). All 18 mutations were detected at 10 plasmid copies per reaction; at a total input of 1 × 105 plasmid copies per reaction, four mutations were detectable at a 0.1% mutant allele fraction and the remaining mutations at 0.5%. No target-specific melting peaks were observed with 293T cell or healthy-donor genomic DNA. In clinical specimens, the MeltArray assay classified 108 specimens as positive and 60 as negative, showing 100% positive, negative, and overall percentage agreement with sequencing. The 131 mutation events comprised 66 in TERT, 45 in IDH1/2, 10 in histone H3, and 10 in BRAF. The MeltArray assay enables rapid, sensitive hotspot genotyping on a standard four-channel real-time PCR platform and is best positioned as a focused adjunct to comprehensive molecular glioma classification.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: